Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2010 1
2011 1
2013 2
2014 1
2015 3
2017 1
2018 2
2019 2
2020 6
2021 13
2022 10
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L. Shi Y, et al. Among authors: wang y. Cancer Commun (Lond). 2022 Dec;42(12):1314-1330. doi: 10.1002/cac2.12385. Epub 2022 Nov 6. Cancer Commun (Lond). 2022. PMID: 36336841 Free PMC article. Clinical Trial.
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, Gu K, Tao M, Wang X, Cui C, Xu N, Xiao J, Gao Q, Liu Y, Zhang T, Bai Y, Li W, Zhang Y, Dai G, Ma D, Zhang J, Bai C, Huang Y, Liao W, Wu L, Chen X, Yang Y, Wang J, Ji S, Zhou H, Wang Y, Ma Z, Wang Y, Peng B, Sun J, Mancao C. Xu J, et al. Among authors: wang y. Nat Commun. 2022 Feb 14;13(1):857. doi: 10.1038/s41467-022-28408-3. Nat Commun. 2022. PMID: 35165274 Free PMC article. Clinical Trial.
Cognitive adverse events in patients with lung cancer treated with checkpoint inhibitor monotherapy: a propensity score-matched analysis.
Ma Y, Liu N, Wang Y, Zhang A, Zhu Z, Zhang Z, Li Y, Jian G, Fu G, Dong M, Zheng G, Zhu P, Zhong G, Bai S, Chen S, Wei X, Tan J, Wang X. Ma Y, et al. Among authors: wang y. EClinicalMedicine. 2023 Apr 27;59:101987. doi: 10.1016/j.eclinm.2023.101987. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37152366 Free PMC article.
Thyroid function and associated mood changes after COVID-19 vaccines in patients with Hashimoto thyroiditis.
Ma Y, Zeng J, Jiang Y, Xu YW, Wang Y, Zhong G, Liu N, Wang Y, Zhang Z, Li Y, Chen S, Wei XL, Zhu P, Jian G, Lyu X, Niu YS, Li M, Liang S, Fu G, He S, Liu C, Zhang A, Wang X. Ma Y, et al. Among authors: wang y. Front Immunol. 2023 Apr 6;14:1129746. doi: 10.3389/fimmu.2023.1129746. eCollection 2023. Front Immunol. 2023. PMID: 37090700 Free PMC article.
Imaging gate-tunable Tomonaga-Luttinger liquids in 1H-MoSe2 mirror twin boundaries.
Zhu T, Ruan W, Wang YQ, Tsai HZ, Wang S, Zhang C, Wang T, Liou F, Watanabe K, Taniguchi T, Neaton JB, Weber-Bargioni A, Zettl A, Qiu ZQ, Zhang G, Wang F, Moore JE, Crommie MF. Zhu T, et al. Nat Mater. 2022 Jul;21(7):748-753. doi: 10.1038/s41563-022-01277-3. Epub 2022 Jun 16. Nat Mater. 2022. PMID: 35710632
57 results